NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, and Center for AIDS Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Medical Oncology, Beijing Hospital, Beijing, China.
Front Immunol. 2022 Jul 22;13:911164. doi: 10.3389/fimmu.2022.911164. eCollection 2022.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines provide essential tools for the control of the COVID-19 pandemic. A number of technologies have been employed to develop SARS-CoV-2 vaccines, including the inactivated SARS-CoV-2 particles, mRNA to express viral spike protein, recombinant spike proteins, and viral vectors. Here, we report the use of the vaccinia virus Tiantan strain as a vector to express the SARS-CoV-2 spike protein. When it was used to inoculate mice, robust SARS-CoV-2 spike protein-specific antibody response and T-cell response were detected. Sera from the vaccinated mice showed strong neutralizing activity against the ancestral Wuhan SARS-CoV-2, the variants of concern (VOCs) B.1.351, B.1.617.2, and the emerging B.1.1.529 (omicron). This finding supports the possibility of developing a new type of SARS-CoV-2 vaccine using the vaccinia virus vector.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）疫苗为控制 COVID-19 大流行提供了重要工具。为了开发 SARS-CoV-2 疫苗，已经采用了多种技术，包括灭活的 SARS-CoV-2 颗粒、表达病毒刺突蛋白的 mRNA、重组刺突蛋白和病毒载体。在这里，我们报告了使用天坛株痘苗病毒作为载体来表达 SARS-CoV-2 刺突蛋白。当将其用于接种小鼠时，检测到了强大的 SARS-CoV-2 刺突蛋白特异性抗体反应和 T 细胞反应。来自接种疫苗的小鼠的血清显示出对原始武汉 SARS-CoV-2、关注变体（VOCs）B.1.351、B.1.617.2 和新兴的 B.1.1.529（奥密克戎）的强烈中和活性。这一发现支持使用痘苗病毒载体开发新型 SARS-CoV-2 疫苗的可能性。
Zotero 插件
